[HTML][HTML] Clinical translation for targeting DNA damage repair in non-small cell lung cancer: a review
Despite significant advancements in screening, diagnosis, and treatment of non-small cell
lung cancer (NSCLC), it remains the primary cause of cancer-related deaths globally. DNA …
lung cancer (NSCLC), it remains the primary cause of cancer-related deaths globally. DNA …
The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung Cancer
Simple Summary DNA-damage repair (DDR) gene alterations are a hallmark for cancer. The
exploitation of DDR alterations has improved outcomes in breast, ovarian, pancreatic, and …
exploitation of DDR alterations has improved outcomes in breast, ovarian, pancreatic, and …
Niraparib for the treatment of metastatic NSCLC in a patient with BRCA2 germinal mutation: A case report
Clinical Practice Points• BRCA1/BRCA2 mutations occur approximately in 2% of NSCLC.•
Here we report a case of a patient with metastatic NSCLC and a germline BRCA2 mutation …
Here we report a case of a patient with metastatic NSCLC and a germline BRCA2 mutation …
BRCA2 mutation in advanced lung squamous cell carcinoma treated with Olaparib and a PD-1 inhibitor: a case report
Z Chen, K Wang, L Zhao, L Gong - Frontiers in Oncology, 2023 - frontiersin.org
Background Mutations in the human breast cancer susceptibility gene 2 (breast cancer 2,
BRCA2) increase the risk of breast, ovarian and other cancers. Olaparib, an oral poly …
BRCA2) increase the risk of breast, ovarian and other cancers. Olaparib, an oral poly …
A novel PARP inhibitor YHP-836 for the treatment of BRCA-deficiency cancers
T Du, Z Zhang, J Zhou, L Sheng, H Yao, M Ji… - Frontiers in …, 2022 - frontiersin.org
PARP inhibitors have clinically demonstrated good antitumor activity in patients with BRCA
mutations. Here, we described YHP-836, a novel PARP inhibitor, YHP-836 demonstrated …
mutations. Here, we described YHP-836, a novel PARP inhibitor, YHP-836 demonstrated …
[PDF][PDF] The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung Cancer. Cancers …
K Khaddour, M Felipe Fernandez, M Khabibov… - 2022 - pdfs.semanticscholar.org
Lung cancer remains the second most commonly diagnosed cancer worldwide and the
leading cause of cancer-related mortality. The map** of genomic alterations and their role …
leading cause of cancer-related mortality. The map** of genomic alterations and their role …